Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- “Big Gap” Remains to Reach 5-Year Profit Target: Astellas Pres.
December 5, 2013
- DSP, Healios Tie Up, Aim to Launch iPS Products in 2018
December 4, 2013
- Ono Joins SGLT-2 Inhibitor Battle via Copromotion Deal with AstraZeneca
December 4, 2013
- Eisai Shakes Up R&D Organization, Paring 130 Jobs in US, Europe
December 4, 2013
- Eisai to Transfer Business Operations at Misato Plant to Bushu Pharmaceuticals
December 4, 2013
- Bayer HealthCare Files Eylea for mCNV in Japan
December 4, 2013
- Reimbursement Listing of Ipragliflozin Expected in April; 4 Rival SGLT-2 Inhibitors Seen to Follow Suit 1 Month Later
December 3, 2013
- Takeda Ready to Welcome Foreign Exec with Open Arms as Company Leader
December 3, 2013
- Japan Gardasil Sales Dive 49.6% in January-September
December 3, 2013
- Merck to Shed 200 Jobs in Japan by 2015
December 3, 2013
- Eisai to Offer Voluntary Retirement Program in Japan
December 3, 2013
- Takeda President Calls GSK Weber Competitive Global Talent, Pushes Globalization
December 2, 2013
- Eisai Files for Approval of Pariet for Preventing Recurrent Ulcers during Aspirin Therapy
December 2, 2013
- GSK Exec Tapped as Takeda’s Next President, 1st Non-Japanese to Lead Japan Juggernaut
December 2, 2013
- AnGes MG to Resume Collategene Development for Critical Limb Ischemia Treatment: President Yamada
November 29, 2013
- No Mortality Cases Reported in Association with Eliquis at PMS: BMKK/Pfizer Japan
November 29, 2013
- MRs, Marketing Division Collaborate to Create Promotional Materials as Part of Pfizer Japan’s New Training Program
November 29, 2013
- President Hasegawa of Takeda Confident About Achieving Targets in Midterm Growth Strategy; Company to Appoint CIO
November 28, 2013
- Teva Japan Pres. Kikushige to Double as Head of Taisho Pharma
November 28, 2013
- Teva Pharma Japan to Temporarily Suspend Supply of Elsamet Combination Tablets
November 28, 2013
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…